LUDWIG ENTERPRISES, INC. (LUDG) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US54973P4019

Price
0.00 USD
Market cap
668,667.59 USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

LUDWIG ENTERPRISES, INC. financials

Fiscal year2025
Operating income-1.77 m USD
EBIT-2.15 m USD
Net income-2.24 m USD
Diluted EPS – continuing operations-0.01 USD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About LUDWIG ENTERPRISES, INC.

Ludwig Enterprises, Inc. operates as a genomic technology focused on developing testing approaches for inflammation-related chronic diseases, including cancers in the United States. The company integrates mRNA inflammatory biomarkers, proprietary machine-learning algorithms, and at-home cheek swab collection kits for cancer identification. It offers mRNA-based screening to provide early insights of potential health risks. The company develops Revealia Breast test, a non-invasive cheek swab screening kit designed to identify and analyze molecular signatures in mRNA expression associated with inflammation-related biological processes associated with the presence of breast cancer. Ludwig Enterprises, Inc. was founded in 1988 and is based in Miami, Florida.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.